XENE

XENON PHARMACEUTICALS INC.

XENE · CIK 1582313 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$346M
20182025
Operating CF−$279M
20182025
Free Cash Flow−$280M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue———————$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.3B$0.2B$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.4B$-0.3B$-0.2B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Net Income$-0.3B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-4.36$-3.01$-2.73$-2.06———$-1.63
EPS (Diluted)$-4.36$-3.01$-2.73$-2.06———$-1.63

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.6B$0.8B$1.0B$0.8B$0.6B$0.2B$0.1B$0.1B
Current Assets$0.6B$0.6B$0.6B$0.6B$0.6B$0.2B$0.1B$0.1B
Cash & Equivalents$0.2B$0.1B$0.1B$0.1B$0.2B$0.0B$0.0B$0.1B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.6B$0.8B$0.9B$0.7B$0.6B$0.2B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.2B$0.2B$-0.1B$-0.3B$-0.2B$-0.0B$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.4B$0.3B$0.4B$0.1B$0.0B$0.1B
← Companies